Adjuvant Capecitabine and Oxaliplatin for Elderly Patients with Colorectal Cancer
Open Access
- 17 October 2022
- journal article
- research article
- Published by S. Karger AG in Oncology
- Vol. 100 (11), 576-582
- https://doi.org/10.1159/000527012
Abstract
Introduction: Adjuvant chemotherapy improves the prognosis of patients with colorectal cancer (CRC) following radical resection. However, the safety and efficacy of oxaliplatin-based chemotherapeutic regimens for elderly patients remains to be elucidated. The aim of the present study was to examine the tolerability and efficacy of adjuvant CAPOX (capecitabine and oxaliplatin) therapy for elderly patients in comparison with young patients. Methods: We examined 138 Japanese patients who received adjuvant CAPOX therapy for high-risk stage II or III CRC between July 2010 and June 2021 at our hospital. Patients were divided according to an age of 70 years. Treatment details of CAPOX therapy were analyzed in association with age. Moreover, prognosis of stage III CRC was compared between the patient groups. Results: Twenty-three patients (17%) were ≥70 years old. Male patients were predominant in the ≥70 years group (p = 0.006). Patients ≥70 years old had more comorbidities (diabetes, p = 0.014; cardiovascular disease, p < 0.001; renal disease, p = 0.042) than patients Conclusions: Adjuvant CAPOX therapy was tolerable in elderly Japanese patients. The prognosis of elderly patients with stage III CRC was similar to that of their younger counterparts. Advanced age itself may not be a contraindication for adjuvant chemotherapy in CRC. Future studies with a larger patient cohort are required to confirm the present results.Keywords
This publication has 24 references indexed in Scilit:
- Impact of Age on the Efficacy of Newer Adjuvant Therapies in Patients With Stage II/III Colon Cancer: Findings From the ACCENT DatabaseJournal of Clinical Oncology, 2013
- Treatment and complications in elderly stage III colon cancer patients in the NetherlandsAnnals of Oncology, 2013
- Bevacizumab plus oxaliplatin-based chemotherapy as adjuvant treatment for colon cancer (AVANT): a phase 3 randomised controlled trialThe Lancet Oncology, 2012
- ESMO Consensus Guidelines for management of patients with colon and rectal cancer. A personalized approach to clinical decision makingAnnals of Oncology, 2012
- Phase III Trial Assessing Bevacizumab in Stages II and III Carcinoma of the Colon: Results of NSABP Protocol C-08Journal of Clinical Oncology, 2011
- Potential Regional Differences for the Tolerability Profiles of FluoropyrimidinesJournal of Clinical Oncology, 2008
- Oxaliplatin Combined With Weekly Bolus Fluorouracil and Leucovorin As Surgical Adjuvant Chemotherapy for Stage II and III Colon Cancer: Results From NSABP C-07Journal of Clinical Oncology, 2007
- Body Composition as an Independent Determinant of 5-Fluorouracil–Based Chemotherapy ToxicityClinical Cancer Research, 2007
- Phase III Trial of Capecitabine Plus Oxaliplatin As Adjuvant Therapy for Stage III Colon Cancer: A Planned Safety Analysis in 1,864 PatientsJournal of Clinical Oncology, 2007
- Fluorouracil plus Levamisole as Effective Adjuvant Therapy after Resection of Stage III Colon Carcinoma: A Final ReportAnnals of Internal Medicine, 1995